Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia

  • Authors:
    • Kyeong Seok Kim
    • Hun Yong Yang
    • Seung‑Cheol Chang
    • Young‑Mi Kim
    • Kwang Youl Lee
    • Byung Mu Lee
    • Hyung Sik Kim
  • View Affiliations

  • Published online on: July 5, 2018     https://doi.org/10.3892/ijmm.2018.3759
  • Pages: 2260-2268
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Benign prostatic hyperplasia (BPH) is one of the leading causes of male reproductive disorders. Therapeutic agents currently in use have severe side effects; therefore, alternative drugs that exhibit improved therapeutic activity without side effects are required. The present study investigated the protective effect of GV1001 against testosterone‑induced BPH in rats. BPH in castrated rats was established via daily subcutaneous (s.c.) injections of testosterone propionate (TP, 3 mg/kg) dissolved in corn oil for 4 weeks. GV1001 (0.01, 0.1 and 1 mg/kg, s.c.) was administered 3 times per week for 4 weeks, together with TP (3 mg/kg) injection. The rats were sacrificed on the last day of treatment, and their prostates were excised and weighed for biochemical and histological studies. Serum levels of testosterone and dihydrotestosterone (DHT) were also measured. In rats with TP‑induced BPH, a significant increase in prostate weight (PW) and prostatic index (PI), accompanied by a decrease in antioxidant enzyme activity, was observed. Histological studies revealed clearly enlarged glandular cavities in rats with BPH. GV1001 (0.01 and 0.1 mg/kg) treatment significantly decreased PW and PI in rats with TP‑induced BPH. In addition, GV1001 demonstrated a potent inhibitory effect on 5α‑reductase in prostate. The present data suggest that the protective role of GV1001 against testosterone‑induced BPH is closely associated with its antioxidant potential. Additional studies are required to identify the mechanisms by which GV1001 protects against BPH to determine its clinical application.

References

1 

Thorpe A and Neal D: Benign prostatic hyperplasia. Lancet. 361:1359–1367. 2003. View Article : Google Scholar : PubMed/NCBI

2 

Lee SWH, Chan EMC and Lai YK: The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep. 7:79842017. View Article : Google Scholar : PubMed/NCBI

3 

Lee YJ, lee JW, Park J, Seo SI, Chung JI, Yoo TK and Son H: Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea. Investig Clin Urol. 57:424–430. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Henry G, Malewska A, Mauck R, Gahan J, Hutchinson R, Torrealba J, Francis F, Roehrborn C and Strand D: Molecular pathogenesis of human prostate basal cell hyperplasia. Prostate. 77:1344–1355. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE and Kaplan SA: Benign prostatic hyperplasia. Nat Rev Dis Primers. 2:160312016. View Article : Google Scholar : PubMed/NCBI

6 

Carson C III and Rittmaster R: The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 61(4 Suppl 1): S2–S7. 2003. View Article : Google Scholar

7 

Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A, Joshi G and Khan SA: The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol. 6:295–304. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM and Zitzmann M: Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know? Rev Endocr Metab Disord. 16:177–198. 2015. View Article : Google Scholar : PubMed/NCBI

9 

La Torre A, Giupponi G, Duffy D, Conca A, Cai T and Scardigli A: Sexual dysfunction related to drugs: A critical review. Part V: α-blocker and 5-ARI drugs. Pharmacopsychiatry. 49:3–13. 2016.

10 

Patel AK and Chappel CR: Benign prostatic hyperplasia, treatment in primary health care. BMJ. 333:535–539. 2006. View Article : Google Scholar : PubMed/NCBI

11 

Srivastava DS and Mittal RD: Free radical injury and antioxidant status in patients with benign prostate hyperplasia and prostate cancer. Indian J Clin Biochem. 20:162–165. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Minciullo PL, Inferrera A, Navarra M, Calapai G, Magno C and Gangemi S: Oxidative stress in benign prostatic hyperplasia: A systematic review. Urol Int. 94:249–254. 2015. View Article : Google Scholar

13 

Jena AK, Vasisht K, Sharma N, Kaur R, Dhingra MS and Karan M: Amelioration of testosterone induced benign prostatic hyperplasia by Prunus species. J Ethnopharmacol. 190:33–45. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Prasad S, Kalra N and Shukla Y: Modulatory effects of diallyl sulfide against testosterone induced oxidative stress in Swiss albino mice. Asian J Androl. 8:719–723. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Siddiquia IA, Raisuddin S and Shukla A: Protective effects of black tea extract on testosterone induced oxidative damage in prostate. Cancer Lett. 227:125–132. 2005. View Article : Google Scholar

16 

Parekh MH, Lobel R, Oconnor LJ, Legget RE and Levin RM: Protective effect of vitamin E on the response of the rabbit bladder to partial outlet obstruction. J Urol. 166:341–346. 2001. View Article : Google Scholar : PubMed/NCBI

17 

Kyte JA: Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs. 18:687–694. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Shaw VE, Naisbitt DJ, Costello E, Greenhalf W, Park BK, Neoptolemos JP and Middleton GW: Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Rev Vaccines. 9:1007–1016. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, Buanes TG and Gaudernack G: Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 95:1474–1482. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Middleton G, Ghaneh P, Costello E, Greenhalf W and Neoptolemos JP: New treatment options for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2:673–696. 2008. View Article : Google Scholar : PubMed/NCBI

21 

Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, Rasmussen AM, Braathen LR and Gaudernack G: Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunother. 60:1553–1564. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G and Aamdal S: Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 17:6847–6857. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Lee YK, Nata'atmaja BS, Kim BH, Pak CS and Heo CY: Protective effect of telomerase-based 16-mer peptide vaccine (gV1001) on inferior epigastric island skin flap survivability in ischaemia-reperfusion injury rat model. J Plast Surg Hand Surg. 51:210–216. 2017. View Article : Google Scholar

24 

Park HH, Yu HJ, Kim S, Kim G, Choi NY, Lee EH, Lee YJ, Yoon MY, Lee KY and Koh SH: Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals. Neurotoxicology. 55:131–141. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Ko YJ, Kwon KY, Kum KY, Lee WC, Baek SH, Kang MK and Shon WJ: The anti-inflammatory effect of human telomerase-derived peptide on P. gingivalis lipopolysaccharide-induced inflammatory cytokine production and its mechanism in human dental pulp cells. Mediators Inflamm. 2015:3851272015. View Article : Google Scholar : PubMed/NCBI

26 

Choi J, Kim H, Kim Y, Jang M, Jeon J, Hwang YI, Shon WJ, Song YW, Kang JS, Lee WJ and Choi J: The anti-inflammatory effect of GV1001 mediated by the downregulation of eno1-induced pro-inflammatory cytokine production. Immune Netw. 15:291–303. 2015. View Article : Google Scholar

27 

Lee MY, Shin IS, Seo CS, Lee NH, Ha HK, Son JK and Shin HK: Effects of Melandrium firmum methanolic extract on testosterone-induced benign prostatic hyperplasia in Wistar rats. Asian J Androl. 14:320–324. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Steers WD: 5alpha-reductase activity in the prostate. Urology. 58(6 Suppl 1): S17–S24. 2001. View Article : Google Scholar

29 

Ali MI, Kondreddi HD and Veeresh B: Protective effect of 2-hydroxy-4-methoxy benzoic acid on testosterone induced benign prostatic hyperplasia in Wister rats. Eur J Pharmacol. 698:397–403. 2013. View Article : Google Scholar

30 

Aydin A, Arsova-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, Ozgök Y and Dimovski A: Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem. 39:176–179. 2006. View Article : Google Scholar : PubMed/NCBI

31 

Sultan C, Paris F, Terouanne B, Balaguer P, Georget V, Poujol N, Jeandel C, Lumbroso S and Nicolas JC: Disorders linked to insufficient androgen action in male children. Hum Reprod Update. 7:314–322. 2001. View Article : Google Scholar : PubMed/NCBI

32 

Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G and Klocker H: Regulation of prostatic growth and function by peptide growth factors. Prostate. 28:392–405. 1996. View Article : Google Scholar : PubMed/NCBI

33 

Jacobsen SJ, Girman CJ and Lieber MM: Natural history of benign prostatic hyperplasia. Urology. 58(6 Suppl 1): S5–S16. 2001. View Article : Google Scholar

34 

Bostanci Y, Kazzazi A, Momtahen S, Laze J and Djavan B: Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 23:5–10. 2013. View Article : Google Scholar

35 

Chung LW, Matsuura J and Runner MN: Tissue interactions and prostatic growth. I Induction of adult mouse prostatic hyperplasia by fetal urogenital sinus implants. Biol Reprod. 31:155–163. 1984. View Article : Google Scholar : PubMed/NCBI

36 

Vral A, Magri V, Montanari E, Gazzano G, Gourvas V, Marras E and Perletti G: Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: A biopsy study in chronic prostatitis patients. Int J Oncol. 41:1950–1958. 2012. View Article : Google Scholar : PubMed/NCBI

37 

Gao M, Ding H, Zhong G, Lu J, Wang H, Li Q and Wang Z: The effects of transrectal radiofrequency hyperthermia on patients with chronic prostatitis and the changes of MDA, NO, SOD, and Zn levels in pretreatment and posttreatment. Urology. 79:391–396. 2012. View Article : Google Scholar

Related Articles

Journal Cover

October 2018
Volume 42 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kim, K.S., Yang, H.Y., Chang, S., Kim, Y., Lee, K.Y., Lee, B.M., & Kim, H.S. (2018). Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia. International Journal of Molecular Medicine, 42, 2260-2268. https://doi.org/10.3892/ijmm.2018.3759
MLA
Kim, K. S., Yang, H. Y., Chang, S., Kim, Y., Lee, K. Y., Lee, B. M., Kim, H. S."Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia". International Journal of Molecular Medicine 42.4 (2018): 2260-2268.
Chicago
Kim, K. S., Yang, H. Y., Chang, S., Kim, Y., Lee, K. Y., Lee, B. M., Kim, H. S."Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia". International Journal of Molecular Medicine 42, no. 4 (2018): 2260-2268. https://doi.org/10.3892/ijmm.2018.3759